Neurocrine Biosciences, Inc.
NBIX
$151.73
-$0.75-0.49%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 794.90M | 687.50M | 572.60M | 627.70M | 622.10M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 794.90M | 687.50M | 572.60M | 627.70M | 622.10M |
| Cost of Revenue | 264.00M | 255.60M | 272.40M | 194.90M | 203.00M |
| Gross Profit | 530.90M | 431.90M | 300.20M | 432.80M | 419.10M |
| SG&A Expenses | 291.60M | 286.30M | 276.50M | 301.80M | 234.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 555.60M | 541.90M | 548.90M | 496.70M | 437.30M |
| Operating Income | 239.30M | 145.60M | 23.70M | 131.00M | 184.80M |
| Income Before Tax | 291.80M | 159.50M | 14.70M | 162.60M | 190.30M |
| Income Tax Expenses | 82.30M | 52.00M | 6.80M | 59.50M | 60.50M |
| Earnings from Continuing Operations | 209.50M | 107.50M | 7.90M | 103.10M | 129.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 209.50M | 107.50M | 7.90M | 103.10M | 129.80M |
| EBIT | 239.30M | 145.60M | 23.70M | 131.00M | 184.80M |
| EBITDA | 247.00M | 152.90M | 31.30M | 138.10M | 191.30M |
| EPS Basic | 2.11 | 1.09 | 0.08 | 1.03 | 1.28 |
| Normalized Basic EPS | 1.64 | 1.05 | 0.28 | 0.96 | 1.29 |
| EPS Diluted | 2.04 | 1.06 | 0.08 | 1.00 | 1.24 |
| Normalized Diluted EPS | 1.59 | 1.03 | 0.28 | 0.93 | 1.25 |
| Average Basic Shares Outstanding | 99.40M | 99.00M | 99.70M | 100.00M | 101.10M |
| Average Diluted Shares Outstanding | 102.50M | 101.00M | 102.50M | 102.90M | 104.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |